SCHEMBL363236

SCHEMBL363236

CCOC(=O)CCN(C)CC(C(=O)OCC)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.48
CHRM1 P11229 1/20 0.45
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
MMP8 P22894 1/20 0.43
KDM4E B2RXH2 2/20 0.42
ALOX5 P09917 1/20 0.42
GAA P10253 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 2/20 0.40
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
POLB P06746 1/20 0.40
UBE2N P61088 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL512958 0.87 SMN1; SMN2 (0.41) LTA4HSMN1; SMN2CYP2C19KDM4EKMT2A
SCHEMBL10257963 0.84 LTA4H (0.50) LTA4HSMN1; SMN2CHRM1CYP3A4CYP2D6
SCHEMBL7288615 0.83 MMP8 (0.49) SMN1; SMN2CYP3A4CYP2D6CYP2C19MMP8
SCHEMBL4481212 0.82 ALOX5 (0.47) LTA4HSMN1; SMN2CHRM1CYP3A4CYP2D6
SCHEMBL5487618 0.81 CHRM1 (0.52) SMN1; SMN2CHRM1MMP8KDM4EGAA
SCHEMBL10291727 0.80 LTA4H (0.46) LTA4HSMN1; SMN2CYP3A4CYP2D6CYP2C19
SCHEMBL6829760 0.80 LTA4H (0.51) LTA4HSMN1; SMN2CYP3A4CYP2D6CYP2C19
SCHEMBL3285667 0.79 ALOX5 (0.55) LTA4HSMN1; SMN2CHRM1CYP3A4CYP2D6
SCHEMBL10574539 0.79 CHRM1 (0.57) SMN1; SMN2CHRM1CYP2D6MMP8KDM4E
SCHEMBL513687 0.77 TDP1 (0.48) LTA4HKDM4EALOX5GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2668168-B1 COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2017-03-01 EP disclosed
EP-2668168-B1 COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2017-03-01 EP disclosed
EP-2593461-B1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2016-08-17 EP disclosed
US-20150336975-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2015-11-26 US disclosed
US-20150336975-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2015-11-26 US disclosed
EP-2459197-B1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2015-10-14 EP disclosed
EP-2459197-B1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2015-10-14 EP disclosed
US-20150152089-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2015-06-04 US disclosed
US-20150152089-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2015-06-04 US disclosed
US-8710061-B2 Compounds for the reduction of β-amyloid production BRISTOL-MYERS SQUIBB COMPANY (US) 2014-04-29 US disclosed
WO-2011014535-A1 COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-03 WO disclosed
EP-0034647-B1 4-ARYLOXY-3-PHENYLPIPERIDINE DERIVATIVES, INTERMEDIATES, A PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS AND THEIR USE AS MEDICAMENTS HOECHST AKTIENGESELLSCHAFT (DE) 1985-06-05 EP disclosed
US-4424357-A Process for preparing 4-aryloxy-3-phenylpiperidines HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1984-01-03 US disclosed
EP-0014997-B1 4-ARYLOXY- AND 4-ARYLTHIO-3-PHENYLPIPERIDINE DERIVATIVES, A PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM HOECHST AKTIENGESELLSCHAFT (DE) 1983-07-20 EP disclosed
US-4382141-A ANTIDEPRESSANTS, ANALGESICS HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1983-05-03 US disclosed
US-4312876-A CENTRAL NERVOUS SYSTEM HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1982-01-26 US disclosed
US-4302590-A THE 4-HYDROXY DERIVATIVE; ANALGESICS, ANTIDEPRESSANTS HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1981-11-24 US disclosed
EP-0034647-A2 4-Aryloxy-3-phenylpiperidine derivatives, intermediates, a process for the preparation of such compounds and their use as medicaments HOECHST AKTIENGESELLSCHAFT (DE) 1981-09-02 EP disclosed
EP-0014997-A1 4-Aryloxy- and 4-arylthio-3-phenylpiperidine derivatives, a process for the preparation of such compounds and pharmaceutical compositions containing them HOECHST AKTIENGESELLSCHAFT (DE) 1980-09-03 EP disclosed
US-4216218-A Antidepressant and analgesic 4-aryloxy- and 4-arylthio-3-phenylpiperidines AMERICAN HOECHST CORPORATION (US) 1980-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152089-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION APP, BACE1, IAPP LTA4H 1848/4885SMN1; SMN2 760/4885CHRM1 1638/4885
US-20150336975-A1 COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION APP, BACE1, IAPP LTA4H 1848/4885SMN1; SMN2 760/4885CHRM1 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.